Frontiers in Oncology (Oct 2022)

Case report: Use of 68Ga-DOTATATE-PET for treatment guidance in complex meningioma disease

  • Anna-Katharina Meißner,
  • Niklas von Spreckelsen,
  • Abdulkader Al Shughri,
  • Anna Brunn,
  • Gina Fuertjes,
  • Marc Schlamann,
  • Marc Schlamann,
  • Matthias Schmidt,
  • Matthias Schmidt,
  • Markus Dietlein,
  • Markus Dietlein,
  • Daniel Rueß,
  • Daniel Rueß,
  • Maximilian I. Ruge,
  • Maximilian I. Ruge,
  • Norbert Galldiks,
  • Norbert Galldiks,
  • Norbert Galldiks,
  • Roland Goldbrunner,
  • Roland Goldbrunner

DOI
https://doi.org/10.3389/fonc.2022.1017339
Journal volume & issue
Vol. 12

Abstract

Read online

Currently, contrast-enhanced MRI is the method of choice for treatment planning and follow-up in patients with meningioma. However, positron emission tomography (PET) imaging of somatostatin receptor subtype 2 (SSTR2) expression using 68Ga-DOTATATE may provide a higher sensitivity for meningioma detection, especially in cases with complex anatomy or in the recurrent setting. Here, we report on a patient with a multilocal recurrent atypical meningioma, in which 68Ga-DOTATATE PET was considerably helpful for treatment guidance and decision-making.

Keywords